PMID- 11241254
OWN - NLM
STAT- MEDLINE
DCOM- 20010419
LR  - 20131121
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 91
IP  - 4
DP  - 2001 Feb 15
TI  - The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool 
      for collecting the invisible costs of androgen independent prostate carcinoma.
PG  - 841-53
AB  - BACKGROUND: There are limited data available regarding the cost of care in 
      patients with androgen independent prostate carcinoma (AIPC), and there are no 
      data on the impact of direct nonmedical and indirect costs (DNM/IC). This lack of 
      data, along with the feasibility of collecting DNM/IC, was examined in patients 
      with AIPC who took part in a randomized trial using a newly developed 
      questionnaire, the Collection of Indirect and Nonmedical Direct Costs (COIN) 
      form. METHODS: Patients with AIPC were randomized to one of three treatment arms: 
      1) strontium only (strontium 4 Mci in Week 1 and Week 12) (STRONT); 2) 
      vinblastine 4 mg/m(2) per week for 3 weeks then 1 week off and estramustine, 10 
      mg/kg per day (CHEMO); or 3) a combination of treatments outlined in the arms for 
      CHEMO and STRONT (CHEMO/STRONT). Direct medical costs were collected through the 
      hospital billing system. DNM/IC data were obtained prospectively using the COIN 
      form. Cost data were analyzed for a period of 6 months. RESULTS: Twenty-nine 
      patients were randomized, after which the protocol was closed because of poor 
      accrual. The median survival of the patients was 22.3 months. The mean and median 
      total costs for the 20 of 29 patients with complete cost information were $12,647 
      and $11,257 over 6 months, respectively. DNM/IC represented 11% of the total cost 
      (range, from < 1% to 42%); in 20% of participating individuals, these costs 
      accounted for 35-42% of total costs. Failure to collect complete cost information 
      was due to early death, administrative difficulties, and loss to follow-up. 
      CONCLUSIONS: In this pilot project, the collection of these cost data using the 
      COIN form was feasible and practical and was limited primarily by logistic, not 
      form specific, issues. DNM/IC were found to be a significant proportion of total 
      costs (up to 42%) in selected patients, and this information proved to be a 
      useful addition to the cost analysis. Approximately 98 patients would be required 
      to detect a 20% difference in total costs between arms in a properly powered, 
      randomized trial. Considering the potentially significant impact on total costs, 
      DNM/IC data should be included in future cost-analysis studies of patients with 
      AIPC and other diseases.
CI  - Copyright 2001 American Cancer Society.
FAU - Sherman, E J
AU  - Sherman EJ
AD  - Division of Solid Tumor Oncology, Department of Medicine, Memorial 
      Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
FAU - Pfister, D G
AU  - Pfister DG
FAU - Ruchlin, H S
AU  - Ruchlin HS
FAU - Rubin, D M
AU  - Rubin DM
FAU - Radzyner, M H
AU  - Radzyner MH
FAU - Kelleher, G H
AU  - Kelleher GH
FAU - Slovin, S F
AU  - Slovin SF
FAU - Kelly, W K
AU  - Kelly WK
FAU - Scher, H I
AU  - Scher HI
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antineoplastic Agents)
RN  - 35LT29625A (Estramustine)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - EKE8PS9J6Z (strontium chloride)
RN  - YZS2RPE8LE (Strontium)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/*economics/secondary
MH  - Aged
MH  - Antineoplastic Agents/*economics/*therapeutic use
MH  - Bone Neoplasms/*drug therapy/*economics/secondary
MH  - *Cost of Illness
MH  - Drug Costs
MH  - Estramustine/economics/therapeutic use
MH  - Health Care Costs
MH  - Health Expenditures
MH  - Hospital Costs
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain/drug therapy/economics/etiology
MH  - Pilot Projects
MH  - Prostatic Neoplasms/*drug therapy/*economics/pathology
MH  - Strontium/economics/therapeutic use
MH  - Vinblastine/economics/therapeutic use
EDAT- 2001/03/10 10:00
MHDA- 2001/04/21 10:01
CRDT- 2001/03/10 10:00
PHST- 2001/03/10 10:00 [pubmed]
PHST- 2001/04/21 10:01 [medline]
PHST- 2001/03/10 10:00 [entrez]
AID - 10.1002/1097-0142(20010215)91:4<841::AID-CNCR1072>3.0.CO;2-B [pii]
PST - ppublish
SO  - Cancer. 2001 Feb 15;91(4):841-53.